High Content Screening Drug Discovery

Discovery of a novel rock2 inhibitor with anti migration effects via docking and high content drug screening 1 january 2016 molecular biosystems vol.

High content screening drug discovery.

High content screening hcs has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of covid 19 and beyond. These types of assays are often referred to as high content screening or high content analysis hcs hca. 1 but the last ten years have certainly disproved those claims with hts playing a role in the discovery of many new drugs and moving from the preserve of large pharma to a method available to smaller companies and even academic institutions. It can be employed in drug discovery projects to optimize compound series on their safety profile and provide a risk assessment tool towards candidate selection.

Drug discovery in its early history used to be conducted mainly in a target agnostic fashion focusing on qualitative readouts from a living system cells tissue or organisms and asking the question did this entity affect the phenotype. 9 high content screening identifies inhibitors of the nuclear translocation of atf6. A decade ago there was talk that high throughput screening hts was a contributory factor in drug discovery s declining productivity and that it stifled creativity and innovation. This demand resulted in the use of cell based screening as a method of choice in drug discovery 1 2 high content screening hcs is multiplexed functional cell based screening 3 4 5 6 hcs can be used in all aspects of drug discovery as an engine for driving.

Paper phenotypic drug discovery with high content screening target based or phenotypic screening. The driving force to adopt imaging for drug development is the quantity and quality of cellular information that can be collected and the enhanced physiological relevance of cellular screening compared to biochemical screening.